N/A N=259 Study Comparing 3 Different Treatments for Arthritis of the Lower Back (Lumbar Spinal Stenosis)
Lumbar Spinal Stenosis
Primary: Swiss Spinal Stenosis (SSS) Questionnaire Score — -2.0; -1.7; -4.1 units on a scale — p=0.73
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=10 Intranasal Administration of Neuropeptide Y in Healthy Male Volunteers
Mood Disorder · Anxiety Disorders
Primary: Levels of NPY in CSF — 329.4; 351.0 pg/mL
Phase 3 N=1,560 Study Comparing Orteronel Plus Prednisone in Participants With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
Prostate Cancer
Primary: Radiographic Progression-free Survival (rPFS) — 8.7; 13.8 months — p=<0.00001
Phase 3 N=462 A Global Study to Compare the Effects of Fulvestrant and Arimidex in a Subset of Patients With Breast Cancer.
Hormone Receptor Positive Breast Cancer
Primary: Comparison of Progression-Free Survival (PFS) in Patients Treated With Fulvestrant With Those Treated With Anastrozole — 16.6; 13.8 Months — p=0.0486
N/A N=21 Differences in Efficacy Between Nasal and Oronasal Masks in the Treatment of OSA With CPAP
Obstructive Sleep Apnea (OSA)
Primary: Comparison of the Effectiveness of Nasal Versus Oronasal CPAP Masks — 332.64; 346.79 minutes
N/A N=26 Dual Epicardial Endocardial Persistent Atrial Fibrillation(AF) Study (Staged DEEP)
Atrial Fibrillation
Primary: Number of Patients With Pre-specified Safety Endpoints Occurring in the First 30 Days Post-index Procedure or Hospital Discharge, Whichever is Longer. — 3 Participants
Phase 2 N=136 Treatment With Mecamylamine in Smoking and Non-smoking Alcohol Dependent Patients
Alcoholism
Primary: Percent Heavy Drinking Days During Active Treatment Phase — 16.75; 24.28; 20.51; 21.78 days
Phase 4 N=75 Methadone Versus Morphine for Orthopedic Surgery Patients
Fracture · Pain, Postoperative
Primary: Opioid Consumption During the 48 Hours After Surgery — 51; 87 mg — p=0.0072
Phase 3 N=206 Efficacy and Safety Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis (ALS)
Amyotrophic Lateral Sclerosis (ALS)
Primary: Change From Baseline in Revised ALS Functional Rating Scale (ALSFRS-R) Score in Full Analysis Set (FAS) Population at 24 Weeks — -5.7; -6.35 units on a scale
Phase 2 N=28 Post-Transplant Bortezomib and High Dose Cyclophosphamide as Graft-Versus-Host Disease (GVHD) Prophylaxis
Hematological Malignancy
Primary: Dose Limiting Toxicity — 0; 0; 0 Participants
N/A N=35 Diagnostic Accuracy of Shear-Wave Elastography for the Preoperative Risk Stratification of Follicular Lesions of the Thyroid
Thyroid Nodule · Follicular Neoplasm
Primary: Shear-Wave Elastography (SWE) Values in kiloPascals (kPa) — 17.50; 31.03; 23.64; 32.14 kPa
Phase 2 N=36 Melphalan, Peripheral Stem Cell Transplantation, and Interleukin-2 Followed by Interferon Alfa in Treating Patients With Advanced Multiple Myeloma
Refractory Multiple Myeloma · Stage I Multiple Myeloma · Stage II Multiple Myeloma
Primary: Overall Survival — 9 Participants
Phase 4 N=112 Evaluation of Two Hand Hygiene Products in ICUs
Hand Hygiene Effectiveness
Primary: Bacterial Colony Forming Units Present on Hand Prints After Time Spent in Common Areas — 2.17; 1.81 log(10) transformed CFU
Phase 3 N=646 Topical Application of Cocaine HCl 4%, or 10%, or Placebo Solution in Local (Topical) Anesthesia
Any Ear Nose or Throat Conditions · With Identified Need for a Diagnostic Procedure or Surgery on or Through the Mucous Membranes of the Nasal Cavities
Primary: Immediate and Sustained Anesthetic Success for Cocaine HCl 4% Topical Solution and Placebo Topical Solution — 0.7093; 0.1969 proportion of participants — p=<0.0001
Phase 2 N=20 Panitumumab in Cetuximab Refractory KRAS Wild-Type Colorectal Cancer
Colorectal Cancer
Primary: Response Rate of Single Agent Panitumumab Among Patients With KRAS Wild-type Colorectal Cancer Previously Treated With Cetuximab. — 0; 9; 10 Participants